Fig. 4: Elevated SUMOylation of FXR in activated HSCs represses its transcriptional activity.
From: SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
a OCA failed to induce the expression of SHP in activated HSCs, caused by CCl4 treatment, BDL operation, and from NASH patients. b SUMOylation of FXR elevated in activated HSCs, caused by CCl4 treatment, BDL operation, and from NASH patients, as analyzed by Protein SUMOylation Assay Ultra Kit. c, d Shp mRNA levels c and FXR SUMOylation d in cells transfected with SUMO1 plasmid. e, f Shp levels e and FXR SUMOylation f in cells transfected with WT or SUMO-site mutant FXR plasmid together with SUMO1 plasmid (n = 3 biologically independent samples within these experiments). Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with Student’s t-test or ANOVA.
